Single-shot, low-dose intratympanic gentamicin in Meniere disease: role of vestibular-evoked myogenic potentials and caloric test in the prediction of outcome

Basit Öğe Kaydı
dc.contributor.authorGode, Sercan
dc.contributor.authorCelebisoy, Nese
dc.contributor.authorAkyuz, Aycan
dc.contributor.authorGulec, Feray
dc.contributor.authorKarapolat, Hale
dc.contributor.authorBilgen, Cem
dc.contributor.authorKirazli, Tayfun
dc.date.accessioned2019-10-27T21:36:36Z
dc.date.available2019-10-27T21:36:36Z
dc.date.issued2011
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to assess the efficacy and safety of single and low-dose intratympanic gentamicin therapy in patients with Meniere disease and who were monitored both with caloric tests and vestibular-evoked myogenic potentials (VEMPs) to see if VEMPs have an additional role in predicting the efficacy of the drug. Study design: This is a prospective cohort study. Setting: Tertiary referral center is the study setting. Patients: Twenty-five intractable Meniere disease patients were included as the study group. Intervention(s): Low-dose (16 mg/mL), single-shot intratympanic gentamicin was applied. VEMP and caloric test were applied 2 weeks after the application. Main outcome measure(s): Safety and efficacy of protocol were evaluated at the sixth month postoperatively with tonal audiogram and visual analog scale, respectively. Results: Mean average pure-tone hearing threshold at 0.5, 1, 2, 4, and 8 kHz was 49.6 and 51.0 dB before and after the application, respectively (P > .05). Mean pretreatment and posttreatment visual analog scale scores of patients were 17.6 mm (10-30 mm) and 74.6 mm (41-100 mm), respectively (P < .01). Posttreatment VEMPs were absent in 17, deteriorated in 2, and not changed in 6 patients. VEMP was a significant predictor of posttreatment visual analog scale score, whereas caloric test was not (P < .01). Conclusions: Low-dose, single-shot intratympanic gentamicin treatment proved to be effective and safe among intractable Meniere patients. VEMPs obtained at posttreatment second week were significant predictors of patients posttreatment sixth-month dizziness status and vertigo control. (C) 2011 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.amjoto.2010.07.021en_US
dc.identifier.endpage416en_US
dc.identifier.issn0196-0709
dc.identifier.issue5en_US
dc.identifier.pmid20851502en_US
dc.identifier.startpage412en_US
dc.identifier.urihttps://doi.org/10.1016/j.amjoto.2010.07.021
dc.identifier.urihttps://hdl.handle.net/11454/46087
dc.identifier.volume32en_US
dc.identifier.wosWOS:000294704200010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherW B Saunders Co-Elsevier Incen_US
dc.relation.ispartofAmerican Journal of Otolaryngologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleSingle-shot, low-dose intratympanic gentamicin in Meniere disease: role of vestibular-evoked myogenic potentials and caloric test in the prediction of outcomeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu